152 related articles for article (PubMed ID: 26571826)
21. Signaling via ErbB2 and ErbB3 associates with resistance and epidermal growth factor receptor (EGFR) amplification with sensitivity to EGFR inhibitor gefitinib in head and neck squamous cell carcinoma cells.
Erjala K; Sundvall M; Junttila TT; Zhang N; Savisalo M; Mali P; Kulmala J; Pulkkinen J; Grenman R; Elenius K
Clin Cancer Res; 2006 Jul; 12(13):4103-11. PubMed ID: 16818711
[TBL] [Abstract][Full Text] [Related]
22. [Radio-chemotherapy in head and neck cancer (EGFR+)].
Ozsahin M; Matzinger O; Zimmermann M; Zouhair A
Bull Cancer; 2007 Sep; 94(9):828-32. PubMed ID: 17878104
[TBL] [Abstract][Full Text] [Related]
23. [Recent advances in molecular-targeted drugs in head and neck cancer].
Tahara M
Gan To Kagaku Ryoho; 2008 May; 35(5):745-52. PubMed ID: 18487911
[TBL] [Abstract][Full Text] [Related]
24. Emerging molecular targeted therapies in the treatment of head and neck cancer.
Bozec A; Peyrade F; Fischel JL; Milano G
Expert Opin Emerg Drugs; 2009 Jun; 14(2):299-310. PubMed ID: 19519286
[TBL] [Abstract][Full Text] [Related]
25. IMC-C225, an anti-epidermal growth factor receptor monoclonal antibody for treatment of head and neck cancer.
Herbst RS; Hong WK
Semin Oncol; 2002 Oct; 29(5 Suppl 14):18-30. PubMed ID: 12422310
[TBL] [Abstract][Full Text] [Related]
26. Epidermal growth factor receptor inhibition in metastatic anal cancer.
Rogers JE; Ohinata A; Silva NN; Mehdizadeh A; Eng C
Anticancer Drugs; 2016 Sep; 27(8):804-8. PubMed ID: 27272412
[TBL] [Abstract][Full Text] [Related]
27. Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy.
Vermorken JB; Trigo J; Hitt R; Koralewski P; Diaz-Rubio E; Rolland F; Knecht R; Amellal N; Schueler A; Baselga J
J Clin Oncol; 2007 Jun; 25(16):2171-7. PubMed ID: 17538161
[TBL] [Abstract][Full Text] [Related]
28. Liquid biopsy monitoring uncovers acquired RAS-mediated resistance to cetuximab in a substantial proportion of patients with head and neck squamous cell carcinoma.
Braig F; Voigtlaender M; Schieferdecker A; Busch CJ; Laban S; Grob T; Kriegs M; Knecht R; Bokemeyer C; Binder M
Oncotarget; 2016 Jul; 7(28):42988-42995. PubMed ID: 27119512
[TBL] [Abstract][Full Text] [Related]
29. AP1G1 is involved in cetuximab-mediated downregulation of ASCT2-EGFR complex and sensitization of human head and neck squamous cell carcinoma cells to ROS-induced apoptosis.
Tao X; Lu Y; Qiu S; Wang Y; Qin J; Fan Z
Cancer Lett; 2017 Nov; 408():33-42. PubMed ID: 28823958
[TBL] [Abstract][Full Text] [Related]
30. Therapies directed against epidermal growth factor receptor in aerodigestive carcinomas.
Karamouzis MV; Grandis JR; Argiris A
JAMA; 2007 Jul; 298(1):70-82. PubMed ID: 17609492
[TBL] [Abstract][Full Text] [Related]
31. Cetuximab in squamous cell carcinoma of the head and neck.
Hitt R; MartÃn P; Hidalgo M
Future Oncol; 2006 Aug; 2(4):449-57. PubMed ID: 16922611
[TBL] [Abstract][Full Text] [Related]
32. Radiolabeled cetuximab: dose optimization for epidermal growth factor receptor imaging in a head-and-neck squamous cell carcinoma model.
Hoeben BA; Molkenboer-Kuenen JD; Oyen WJ; Peeters WJ; Kaanders JH; Bussink J; Boerman OC
Int J Cancer; 2011 Aug; 129(4):870-8. PubMed ID: 20957635
[TBL] [Abstract][Full Text] [Related]
33. Anti EGFR therapy in the treatment of non-metastatic head and neck squamous cell carcinoma: The current evidence.
Benson R; Mallick S; Julka PK; Rath GK
J Egypt Natl Canc Inst; 2016 Sep; 28(3):141-8. PubMed ID: 27160750
[TBL] [Abstract][Full Text] [Related]
34. Cetuximab and radiotherapy for head and neck cancer.
Posner MR; Wirth LJ
N Engl J Med; 2006 Feb; 354(6):634-6. PubMed ID: 16467552
[No Abstract] [Full Text] [Related]
35. Treatment of advanced head and neck cancer with cetuximab.
Merlano M; Garrone O
Int J Biol Markers; 2007; 22(1 Suppl 4):S71-6. PubMed ID: 17520584
[TBL] [Abstract][Full Text] [Related]
36. Emerging molecular targeted therapies in squamous cell carcinoma of the head and neck.
Gilbert J; Argiris A
Clin Adv Hematol Oncol; 2006 Aug; 4(8):611-9. PubMed ID: 17099619
[TBL] [Abstract][Full Text] [Related]
37. More on cetuximab in head and neck cancer.
Mell LK; Weichselbaum RR
N Engl J Med; 2007 Nov; 357(21):2201-2; author reply 2202-3. PubMed ID: 18032774
[No Abstract] [Full Text] [Related]
38. Cilengitide and Cetuximab Reduce Cytokine Production and Colony Formation of Head and Neck Squamous Cell Carcinoma Cells
Wichmann G; Cedra S; Schlegel D; Kolb M; Wiegand S; Boehm A; Hofer M; Dietz A
Anticancer Res; 2017 Feb; 37(2):521-527. PubMed ID: 28179297
[TBL] [Abstract][Full Text] [Related]
39. Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor.
Huang S; Armstrong EA; Benavente S; Chinnaiyan P; Harari PM
Cancer Res; 2004 Aug; 64(15):5355-62. PubMed ID: 15289342
[TBL] [Abstract][Full Text] [Related]
40. ErbB activation signatures as potential biomarkers for anti-ErbB3 treatment in HNSCC.
Alvarado D; Ligon GF; Lillquist JS; Seibel SB; Wallweber G; Neumeister VM; Rimm DL; McMahon G; LaVallee TM
PLoS One; 2017; 12(7):e0181356. PubMed ID: 28723928
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
